Physician profile
Kenneth M Eakin
NPI 1174529556
$2,010.34
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $716 · 2021: $112.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $568.36 | 2019-2020 | |
| Novo Nordisk INC | $175.70 | 2019 | |
| Pfizer INC. | $146.79 | 2019 | |
| Lilly USA, LLC | $128.18 | 2019-2020 | |
| Amarin Pharma, INC. | $120.15 | 2019-2020 | |
| Amgen INC. | $101.27 | 2019-2020 | |
| Abbvie INC. | $91.80 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $91.29 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $88.03 | 2019-2020 | |
| Astellas Pharma US INC | $69.65 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.67 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.36 | 2019 | |
| Abbott Laboratories | $34.78 | 2021 | |
| Glaxosmithkline, LLC. | $33.72 | 2019 | |
| Jazz Pharmaceuticals INC. | $32.95 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.37 | 2019 | |
| Shire North American Group INC | $27.88 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.41 | 2019 | |
| Celgene Corporation | $19.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.67 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.68 | 2019 | |
| Antares Pharma, INC. | $13.36 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.92 | 2020 | |
| Sanofi Pasteur INC. | $11.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Eakin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.